OSR Health, Inc. received a Staff Determination Letter from Nasdaq notifying the company of its intent to delist common stock and warrants for non-compliance with the minimum bid price requirement. On August 25, 2026, OSR Health submitted a request for a hearing before a Nasdaq Hearings Panel to appeal this determination. Although the timely hearing request will not stay the scheduled suspension of trading on August 26, 2026, it is expected to prevent the immediate filing of Form 25-NSE pending the panel's decision. The company intends to present a compliance plan at the hearing but provided no assurance that listing would be maintained. OSR Health operates in the healthcare sector, providing medical equipment and services.

OSR Health, Inc. received a Staff Determination Letter from Nasdaq notifying it of the delisting of its common stock and warrants due to failure to maintain the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Trading is scheduled to be suspended on August 26, 2026, though a hearing request filed by August 26 may stay the final delisting pending a Panel decision. The company cites extraordinary trading volume of approximately 370 million shares on August 17 and an intraday price high of $0.84 as grounds for appeal. OSR Health operates in the healthcare sector, focusing on biomedical innovations including immuno-oncology, regenerative biologics, and medical device technologies.

OSR Health, Inc. changed its corporate name from OSR Holdings, Inc. to OSR Health, Inc. effective June 11, 2026, via a Certificate of Revival of Charter filed with the State of Delaware. The name change was approved by the Board of Directors and did not require stockholder-level approval under Delaware law. OSR Health, Inc. operates in the healthcare sector and provides health-related services or products.

OSR Holdings, Inc. entered into an Asset Purchase Agreement with its subsidiary, Vaximm AG, to acquire outright ownership of the VXM01 intellectual property family. The transaction involves an aggregate purchase price of $30,000,000, which becomes due upon the completion of a Phase 2 clinical study of VXM01 in either glioblastoma or pancreatic ductal adenocarcinoma.